论文部分内容阅读
目的探讨丹参酮ⅡA磺酸钠对早期糖尿病肾病(DN)患者血清转化生长因子β1(TGF-β1)和Ⅳ型胶原(CⅣ)水平的影响。方法 64例早期DN患者随机分为两组,对照组(32例)采用糖尿病常规治疗,治疗组(32例)在常规治疗基础上加用丹参酮ⅡA磺酸钠,疗程均为1个月。采用ELISA法测定两组患者治疗前后血清TGF-β1、CⅣ水平,同时观察尿白蛋白排泄率(UAER)的变化。结果治疗组患者治疗后血清TGF-β1、CⅣ水平明显下降(P<0.01);对照组血清TGF-β1、CⅣ水平治疗前后比较无明显变化(P>0.05)。两组治疗后UAER均较治疗前降低,治疗组降低更明显(P<0.01)。结论丹参酮ⅡA磺酸钠可降低早期DN患者的血清TGF-β1、CⅣ水平,延缓DN的发展。
Objective To investigate the effects of tanshinone Ⅱ A sulfonate on serum levels of transforming growth factor β1 (TGF-β1) and collagen Ⅳ (Ⅳ) in patients with early diabetic nephropathy (DN). Methods Sixty-four patients with early DN were randomly divided into two groups. The control group (n = 32) was treated with conventional diabetes. The treatment group (n = 32) was given tanshinone Ⅱ A sulfonate on the basis of routine treatment. The course of treatment was 1 month. Serum levels of TGF-β1 and CⅣ in both groups before and after treatment were measured by ELISA. Urinary albumin excretion rate (UAER) was also observed. Results Serum levels of TGF-β1 and CⅣ in the treatment group decreased significantly (P <0.01). The levels of TGF-β1 and CⅣ in the control group had no significant changes before and after treatment (P> 0.05). UAER after treatment in both groups were lower than before treatment, the treatment group decreased more significantly (P <0.01). Conclusion Sodium tanshinone Ⅱ A sulfonate can reduce the serum levels of TGF-β1 and CⅣ in DN patients and delay the development of DN.